MENU
+Compare
EDIT
Stock ticker: NASDAQ
AS OF
Apr 24, 04:59 PM (EDT)
Price
$1.61
Change
+$0.05 (+3.21%)
Capitalization
134.77M

EDIT Editas Medicine Forecast, Technical & Fundamental Analysis

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases... Show more

Industry: #Biotechnology
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for EDIT with price predictions
Apr 23, 2025

EDIT's RSI Indicator recovers from oversold territory

The RSI Oscillator for EDIT moved out of oversold territory on April 09, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 44 similar instances when the indicator left oversold territory. In of the 44 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on April 11, 2025. You may want to consider a long position or call options on EDIT as a result. In of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for EDIT just turned positive on April 11, 2025. Looking at past instances where EDIT's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

EDIT moved above its 50-day moving average on April 22, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in of 243 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The 10-day moving average for EDIT crossed bearishly below the 50-day moving average on March 19, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

EDIT broke above its upper Bollinger Band on April 22, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for EDIT entered a downward trend on April 16, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.973) is normal, around the industry mean (14.056). P/E Ratio (0.000) is within average values for comparable stocks, (63.446). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.788). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (3.975) is also within normal values, averaging (252.992).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EDIT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

EDIT is expected to report earnings to rise 1.29% to -55 cents per share on April 30

Editas Medicine EDIT Stock Earnings Reports
Q1'25
Est.
$-0.56
Q4'24
Missed
by $0.22
Q3'24
Est.
$-0.75
Q2'24
Missed
by $0.12
Q1'24
Missed
by $0.13
The last earnings report on March 05 showed earnings per share of -55 cents, missing the estimate of -33 cents. With 1.11M shares outstanding, the current market capitalization sits at 134.77M.
A.I. Advisor
published General Information

General Information

a company which translates genome editing technology into a novel class of human therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
11 Hurley Street
Phone
+1 617 401-9000
Employees
265
Web
https://www.editasmedicine.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AABFX13.440.09
+0.67%
Thrivent Dynamic Allocation A
QDISX15.70N/A
N/A
Fisher IIG Stock for Ret Plns
ODICX36.44N/A
N/A
Invesco Discovery C
NSOPX15.35N/A
N/A
North Star Opportunity A
GGHSX36.76N/A
N/A
Invesco Health Care R6

EDIT and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been loosely correlated with CRSP. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if EDIT jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
N/A
CRSP - EDIT
53%
Loosely correlated
-1.76%
AXON - EDIT
52%
Loosely correlated
+3.82%
PRME - EDIT
51%
Loosely correlated
+4.14%
VCYT - EDIT
49%
Loosely correlated
+1.08%
NTLA - EDIT
49%
Loosely correlated
-2.65%
More